11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE MALEATE SALT
    1.
    发明公开
    11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE MALEATE SALT 有权
    11-(2-吡咯烷-1-基 - 乙氧基)-14,19二氧杂5,7,26三氮杂 - 四环[19.3.1.1(2,6)0.1(8,12)]二十七-1( 25),2(26),3,5,8,10,12(27),16,21,23-十氢马来酸盐

    公开(公告)号:EP2376500A1

    公开(公告)日:2011-10-19

    申请号:EP09793626.4

    申请日:2009-12-09

    申请人: S*BIO Pte Ltd

    CPC分类号: C07D498/04

    摘要: The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19- dioxa-5,7,26triaza-tetra-cyclo[19.3.1.1 (2,6).1 (8, 12)]heptacosa-1 (25),2(26),3,5,8, 10, 12(27), 16,21, 23-decaene Compound (I) which have been found to have improved properties. In particular the present invention relates to the maleate salt of this compound. The invention also relates to pharmaceutical compositions containing this salt and methods of use of the salt in the treatment of certain medical conditions.

    摘要翻译: 本发明涉及11-(2-吡咯烷-1-基 - 乙氧基)-14,19-二氧杂-5,7,26-三氮杂 - 四环[19.3.1.1(2,6).1( (25),2(26),3,5,8,10,12(27),16,21,23-十烯化合物(I),它们具有改进的性能。 具体地说,本发明涉及该化合物的马来酸盐。 本发明还涉及含有该盐的药物组合物以及该盐在治疗某些医学病症中的使用方法。

    9E-15-(2-PYRROLIDIN-1-YL-ETHOXY)-7,12,25-TRIOXA-19,21,24-TRIAZA- TETRACYCLO[18.3.1.1(2,5).1(14)18)]HEXACOSA-1(24),2,4,9,14,16,18(26),20,22-NONAENE CITRATE SALT
    4.
    发明公开
    9E-15-(2-PYRROLIDIN-1-YL-ETHOXY)-7,12,25-TRIOXA-19,21,24-TRIAZA- TETRACYCLO[18.3.1.1(2,5).1(14)18)]HEXACOSA-1(24),2,4,9,14,16,18(26),20,22-NONAENE CITRATE SALT 有权
    9E-15-(2-吡咯烷-1-基 - 乙氧基)-7,12,25-三氧杂壬烷-19,21,24-三氮杂 - 四环[18.3.1.1(2,5).1(14)18)] HEXACOSA-1(24),2,4,9,14,16,18(26),20,22-NONAENE CITRATE SALT

    公开(公告)号:EP2454266A1

    公开(公告)日:2012-05-23

    申请号:EP10737645.1

    申请日:2010-07-14

    申请人: S Bio Pte Ltd

    CPC分类号: C07D498/18

    摘要: The present invention relates to certain salts of a 9E-15-(2-pyrrolidin-1-yl-ethoxy)- 7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1 (2,5).1(14,18)]hexacosa-1 (24),2,4,9,14,16,18(26),20,22-nonaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use of the citrate salt in the treatment of certain medical conditions.

    摘要翻译: 本发明涉及9E-15-(2-吡咯烷-1-基 - 乙氧基)-7,12,25-三氧杂-19,21,24-三氮杂 - 四环[18.3.1.1(2,5 ).1(14,18)]二十六碳-1(24),2,4,9,14,16,18(26),20,22-壬烯(化合物I),它们已被发现具有改进的性能。 具体地说,本发明涉及该化合物的柠檬酸盐。 本发明还涉及含有柠檬酸盐的药物组合物和使用该柠檬酸盐治疗某些医学病症的方法。